Home › Companies › CHRS

Coherus Oncology

Market cap $74.0M 154.5M shares (10-Q, Oct 31, 2026) × $0.479 close Nov 17, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Tagmokitug + pasritamig Ph1 startFall 2026Tagmokitug + pasritamig Ph1 start, Fall 2026, routine
  2. Casdozokitug Ph2 topline1H 2027Casdozokitug Ph2 topline, 1H 2027, thesis-defining
  3. company financing1Q 2027company financing, 1Q 2027, routine
  4. UDENYCA corporate updateMar 31, 2027UDENYCA corporate update, Mar 31, 2027, routine
  5. Term B Loan corporate updateSep 1 – Apr 30, 2028Term B Loan corporate update, Sep 1 – Apr 30, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

TREGCHECK

Clinical development program platform evaluating tagmokitug (anti-CCR8 cytolytic antibody) across multiple solid tumor settings, including ESCC, HNSCC, gastric/GEJ/esophageal, and colorectal cancers; focused on CCR8-positive regulatory T cell depletion to overcome immune resistance

Targets: CCR8

Discontinued (1)

Capital (as filed)

Cash
$53.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$30.1M Sep 30, 2026
Operating cash flow
−$34.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$83.6M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Coherus Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Coherus Oncology (CHRS) — Scientific Deep Dive for LOQTORZI, Casdozokitug, and Tagmokitug The mid-2026 casdozokitug Phase 2 randomized readout is a binary coin flip; the author recommends waiting for data rather than committing capital ahead of an unknowable 72-patient outcome.
  2. Speculative buy speculative UPDATE: Coherus Oncology (CHRS) - The Coin Flip Moved to October Enrollment is complete on the casdozo HCC Phase 2, the catalyst now has a named month (early October), and opex is genuinely shrinking — sufficient to justify a first tranche for binary-event investors, sized to survive a 60% drawdown.
  3. Hold UPDATE: Coherus Oncology (CHRS) - They Funded the Coin Flip The $55M Innovatus debt facility removes the pre-readout dilutive equity raise risk, but the capital structure is now heavier with a senior IP lien and a liquidity covenant, shifting the risk/reward geometry enough to step back from Speculative Buy to Hold for those not yet positioned.
  4. Hold UPDATE: Coherus Oncology (CHRS) - They Reloaded the ATM The new $50M Leerink ATM adds a dilution vector at management's discretion but does not change the underlying binary setup; the catalyst is intact roughly five weeks out and the verdict remains Hold.
  5. Hold UPDATE: Coherus Oncology (CHRS) - Tagmokitug Finally Shows Its Cards Tagmokitug's 6/8 response rate in 1L ESCC provides genuine proof-of-concept with denominators, but the sample is tiny, the 2L HNSCC cohort missed the bar, and the casdozokitug binary remains the dominant value driver — no change warranted for existing holders.
  6. Avoid UPDATE: Coherus Oncology (CHRS) - The Coin Flip Outran the Cash The casdozokitug binary slipped to 1H 2027, a going-concern warning appeared, the Innovatus covenant floor may have risen above available free cash, and a dilutive equity raise ahead of the readout is now the base case — whoever buys equity today is likely to be diluted before the coin is flipped.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)